Аналитики Barclays и H.C. Wainwright повысили рейтинг акций SAB Biotherapeutics до «Покупать»

Аналитики Barclays и H.C. Wainwright рекомендовали инвесторам приобрести акции SAB Biotherapeutics, указав на недооцененный потенциал препарата для лечения диабета 1 типа. Эксперты считают, что текущая рыночная капитализация компании в 300 миллионов долларов не отражает возможную прибыль в 4 миллиарда долларов от успешных клинических испытаний.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

SAB Biotherapeutics, Inc. (NASDAQ:SABS) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. Back-to-back bullish analyst calls are pointing to a wide gap between the company's market value and the opportunity Wall Street sees in its lead diabetes program. On June 24, 2026, Barclays analyst Eliana Merle initiated coverage of SAB Biotherapeutics, Inc. (NASDAQ:SABS) with an "Overweight" rating and a $13 price target. Merle told investors the type 1 diabetes market is large and that SAB-142 could represent a significant opportunity as a potential disease modifying therapy. According to the firm, the next major catalyst for the stock is SAB's Phase 2b data expected in the second half of 2027, while Tzield's recent approval has reduced regulatory uncertainty surrounding SAB-142. Barclays argued that SAB Biotherapeutics, Inc. (NASDAQ:SABS)'s $300 million market capitalization fails to reflect the potential $4 billion market opportunity for SAB-142 in type 1 diabetes therapy. That view followed a June 15, 2026 note from H.C. Wainwright analyst Emily Bodnar, who maintained a "Buy" rating on SAB Biotherapeutics, Inc. (NASDAQ:SABS) with a $10 price target. Bodnar said Sanofi's accelerated approval of Tzield in Stage 3 type 1 diabetes validates the use of C-peptide as a surrogate endpoint, reducing development risk for SAB-142's ongoing SAFEGUARD trial. She also cited differentiation from Tzield and rabbit ATG on safety and immunogenicity, minimal immune-related toxicities in early data, and support for a twice-yearly maintenance regimen as reasons behind the firm's positive risk-reward view on SAB Biotherapeutics, Inc. (NASDAQ:SABS). SAB Biotherapeutics, Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company that focuses on the development of human polyclonal immunotherapeutic antibodies. Its main product candidate is SAB-142 for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. While we acknowledge the potential of SABS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. Disclosure: None. Follow Insider Monkey on Google News.